Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Glucagon, Glucose Monitoring, Other, SGLT2i May 09 | 2023AZ’s Farxiga Receives FDA Approval for DELIVER; Esperion, Xeris, Madrigal, and Sigilon Q1 ’23 Earnings; Ascensia Expands Eversense PASS Program; and Glooko Redesigns AppPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other May 08 | 2023Akebia and Viatris Q1 ’23 EarningsPurchase Blast
$599
Posted in: Insulin Delivery, Other May 05 | 2023Insulet Q1 ’23 Earnings and Organizational Changes; Tidepool Secures Funding to Support Tidepool Loop for AndroidPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Insulin Delivery, Other May 04 | 2023Novo Nordisk, Tandem, Alnylam, and Regeneron Q1 ’23 EarningsPurchase Blast
$599
Posted in: Other, SGLT2i May 03 | 2023Ionis, Lexicon, and Amarin Q1 ’23 Earnings; AstraZeneca Collaborates with Sernova for Cell TherapiesPurchase Blast
$599
Posted in: GLP-1RA, Other May 02 | 2023D&D Pharmatech Announces Positive Ph1 DD01 NAFLD Topline Results; FDA Clears NeuroBo’s IND for Ph2a DA-1241 NASH Trial; Pfizer Q1 ’23 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Other May 01 | 2023Vertex Q1 ’23 Earnings; Lannett Restructures Debt and Files for BankruptcyPurchase Blast
$599
Posted in: Glucose Monitoring, Other Apr 28 | 2023Dexcom, Amgen, and Merck Q1 ’23 Earnings; JDRF and Humacyte Collaborate on Insulin-Producing Biovascular Pancreas for T1DMPurchase Blast
$599
Posted in: Basal Insulin, Other, SGLT2i Apr 27 | 2023Intercept, AZ, and Sanofi Q1 ’23 Earnings; Sanofi Completes Provention Acquisition; DRI Sells Tzield Royalties to SanofiPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, Other Apr 27 | 2023Lilly to Use PRV for Tirzepatide Obesity Submission Following Positive SURMOUNT-2 Topline Results; Lilly, Viking, and Teladoc Q1 ’23 EarningsPurchase Blast
$599
Posted in: Insulin Delivery, Other Apr 26 | 2023Medtronic Resolves FDA Warning Letter; HSR Waiting Period for Sanofi’s Provention Bio Acquisition Expires; Roche Q1 ’23 EarningsPurchase Blast
$599
Posted in: Insulin Delivery, Other Apr 25 | 2023Novartis Q1 ’23 Earnings; Insulet Basal-Only T2DM Pod Receives FDA Clearance; Vadadustat Approved by EC; Sernova Announces Positive T1DM Preclinical Data with Evotec’s iPSC-Derived ILCsPurchase Blast
$599
Posted in: Glucagon, Glucose Monitoring, Insulin Delivery, Other Apr 24 | 2023Lilly to Divest Baqsimi to Amphastar; Medtronic 780G+GS4 FDA Approval; April CHMP AgendaPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist Apr 21 | 2023Lilly Initiates SURMOUNT H2H Obesity Trial vs. Wegovy; Lannett Delisted from NYSE; Novo Initiates Ph3 Icodec ONWARDS 9 CGM Trial; Senate Targets PBMsPurchase Blast
$599
Posted in: Glucose Monitoring, Other Apr 19 | 2023Abbott Q1 '23 Earnings; Eversense 365-Day Sensor Inserted Into First Pediatric Patient; Esperion Partners With Currax for Nexletol/Nexlizet Promotion; Zucara ZT-01 Ph2 T1DM IND ClearedPurchase Blast
$599
Posted in: Other Apr 19 | 2023Resmetirom Receives Breakthrough Therapy Designation; Tiziana Initiates Foralumab T1DM Program; Teladoc Expands Provider-Based Care; J&J Q1 '23 EarningsPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Apr 17 | 2023Lilly Invests $1.6B in Indiana Manufacturing; Dexcom and Abbott Highlight Medicare CGM Coverage Expansion; Tandem Announces Positive Control-IQ Meta-AnalysisPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA + Basal, Glucose Monitoring Apr 14 | 2023Lilly Completes SURMOUNT-2 Trial; FDA Clears Libre 3 Reader; Novo Initiates Ph3 Icodec + Semaglutide Treatment Intensification TrialPurchase Blast
$599
Posted in: GLP-1RA, Other Apr 13 | 2023Novo Raises 2023 Guidance; Sana Biotechnology Appoints New R&D Leaders and Announces Publication of Pre-Clinical DataPurchase Blast
$599
Posted in: Dual/triple agonist, Other Apr 12 | 2023New Tirzepatide Injection Device Trial; Novo Partners with Aspect Biosystems; Sanofi’s Provention Bio Acquisition Regulatory Issue; Glooko Partners with HediaPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
